Heterobicyclic compounds of Formula (I):
or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.
Formula (I)的杂环化合物:
或其药用可接受的盐、互变异构体或立体异构体,如规范中所定义,并含有它们的组合物,以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法,如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
申请人:AbbVie Inc.
公开号:US20170355769A1
公开(公告)日:2017-12-14
The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
A General Approach to Substituted Benzimidazoles and Benzoxazoles
<i>via</i>
Heterogeneous Palladium‐Catalyzed Hydrogen‐Transfer with Primary Amines
作者:Marianna Pizzetti、Elisa De Luca、Elena Petricci、Andrea Porcheddu、Maurizio Taddei
DOI:10.1002/adsc.201200253
日期:2012.9.17
employed. Primaryamines are the most suitable reagents for the atom economy of the overall process that resulted to be general as several different substitutedbenzimidazoles were obtained in good yield. Benzoxazoles can be also prepared starting from primaryamines and o‐aminophenol. The reaction is also highly selective as no (poly)‐alkylated phenylenediamines or cross‐contaminated benzimidazoles are
CuI-Catalyzed Amination of Arylhalides with Guanidines or Amidines: A Facile Synthesis of 1-<i>H</i>-2-Substituted Benzimidazoles
作者:Xiaohu Deng、Heather McAllister、Neelakandha S. Mani
DOI:10.1021/jo900912h
日期:2009.8.7
CuI/L5 (N,N′-dimethylethylenediamine) proves to be an efficient catalyst system for the amination of arylhalides with guanidines. The same catalyst system is then successfully applied to the one-step synthesis of 1-H-2-amino-benzimidazoles through tandem aminations of 1,2-dihaloarenes in modest yields. This methodology is also applicable for the preparation of 1-H or 1-substutituted 2-aryl- or 2-alkyl-benzimidazoles
事实证明,CuI / L5(N,N'-二甲基乙二胺)是一种用于将芳基卤化物与胍胺化的有效催化剂体系。然后将相同的催化剂体系成功地通过1,2-二卤代芳烃的串联胺化以适度的产率成功地一步合成1- H -2-氨基-苯并咪唑。该方法学也可用于制备1- H或1-取代的2-芳基-或2-烷基-苯并咪唑。
SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
申请人:BlinkBio, Inc.
公开号:US20170202970A1
公开(公告)日:2017-07-20
Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.